Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (SNDX) announced the granting of inducement awards to five new employees on January 1, 2025. The awards consist of stock options to purchase up to 123,100 shares of common stock under the Company's 2023 Inducement Plan. The vesting schedule spans four years, with 25% of shares vesting after the first year and the remaining 1/48th vesting monthly over the subsequent 36 months, contingent on continued employment with Syndax.
Syndax Pharmaceuticals (SNDX) ha annunciato l'assegnazione di premi di indennità a cinque nuovi dipendenti il 1° gennaio 2025. I premi consistono in opzioni su azioni per l'acquisto di fino a 123.100 azioni ordinarie nell'ambito del Piano di Indennità 2023 della Società. Il piano di maturazione si estende su quattro anni, con il 25% delle azioni che maturano dopo il primo anno e il restante 1/48 che matura mensilmente nei successivi 36 mesi, a condizione che il dipendente rimanga in servizio presso Syndax.
Syndax Pharmaceuticals (SNDX) anunció la concesión de premios de inducción a cinco nuevos empleados el 1 de enero de 2025. Los premios consisten en opciones sobre acciones para comprar hasta 123,100 acciones ordinarias bajo el Plan de Inducción 2023 de la compañía. El calendario de adquisición se extiende por cuatro años, con el 25% de las acciones adquiriéndose después del primer año y el restante 1/48 adquiriéndose mensualmente durante los siguientes 36 meses, condicionado a la continuación del empleo con Syndax.
신닥스 제약(SNDX)는 2025년 1월 1일에 5명의 신규 직원에게 유인 보상을 부여한다고 발표했습니다. 이 보상은 회사의 2023 유인 계획에 따라 123,100주의 보통주를 구매할 수 있는 주식 옵션으로 구성됩니다. 취득 일정은 4년에 걸쳐 진행되며, 첫 해에 25%의 주식이 취득되고 나머지 1/48은 이후 36개월 동안 매달 취득됩니다. 이는 신닥스에서 계속 근무하는 조건입니다.
Syndax Pharmaceuticals (SNDX) a annoncé la concession de primes d'incitation à cinq nouveaux employés le 1er janvier 2025. Les primes consistent en des options d'achat d'actions permettant d'acquérir jusqu'à 123 100 actions ordinaires dans le cadre du Plan d'Incitation 2023 de l'entreprise. Le calendrier d'acquisition s'étend sur quatre ans, avec 25% des actions acquises après la première année et le reste 1/48 acquis mensuellement pendant les 36 mois suivants, sous réserve de maintien de l'emploi chez Syndax.
Syndax Pharmaceuticals (SNDX) kündigte die Gewährung von Anreizoptionen für fünf neue Mitarbeiter am 1. Januar 2025 an. Die Auszeichnungen bestehen aus Aktienoptionen zum Kauf von bis zu 123.100 Aktien des Stammkapitals gemäß dem Anreizplan 2023 des Unternehmens. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25% der Aktien nach dem ersten Jahr und die verbleibenden 1/48 monatlich über die folgenden 36 Monate erworben werden, vorausgesetzt, der Mitarbeiter bleibt bei Syndax beschäftigt.
- Addition of five new employees indicates company growth
- Implementation of employee retention strategy through stock options
- Potential future dilution of existing shareholders due to 123,100 new stock options
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302341648.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
How many shares were granted in SNDX's January 2025 inducement awards?
What is the vesting schedule for SNDX's January 2025 inducement grants?
How many employees received SNDX inducement grants in January 2025?
Under which plan were SNDX's January 2025 inducement awards granted?
